↓ Skip to main content

Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4

Overview of attention for article published in Oncogene, August 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

news
1 news outlet
twitter
6 X users

Readers on

mendeley
86 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4
Published in
Oncogene, August 2016
DOI 10.1038/onc.2016.256
Pubmed ID
Authors
Abstract

Fatty acid binding protein 4 (FABP4) is a fatty acid chaperone, which is induced during adipocyte differentiation. Previously we have shown that FABP4 in endothelial cells is induced by the NOTCH1 signalling pathway, the latter of which is involved in mechanisms of resistance to antiangiogenic tumour therapy. Here, we investigated the role of FABP4 in endothelial fatty acid metabolism and tumour angiogenesis. We analysed the effect of transient FABP4 knockdown in human umbilical vein endothelial cells on fatty acid metabolism, viability and angiogenesis. Through therapeutic delivery of siRNA targeting mouse FABP4, we investigated the effect of endothelial FABP4 knockdown on tumour growth and blood vessel formation. In vitro, siRNA-mediated FABP4 knockdown in endothelial cells led to a marked increase of endothelial fatty acid oxidation, an increase of reactive oxygen species and decreased angiogenesis. In vivo, we found that increased NOTCH1 signalling in tumour xenografts led to increased expression of endothelial FABP4 that decreased when NOTCH1 and VEGFA inhibitors were used in combination. Angiogenesis, growth and metastasis in ovarian tumour xenografts were markedly inhibited by therapeutic siRNA delivery targeting mouse endothelial FABP4. Therapeutic targeting of endothelial FABP4 by siRNA in vivo has antiangiogenic and antitumour effects with minimal toxicity and should be investigated further.Oncogene advance online publication, 29 August 2016; doi:10.1038/onc.2016.256.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 86 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Japan 1 1%
Unknown 85 99%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 14 16%
Student > Ph. D. Student 10 12%
Student > Bachelor 9 10%
Student > Doctoral Student 5 6%
Student > Master 5 6%
Other 15 17%
Unknown 28 33%
Readers by discipline
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 15 17%
Agricultural and Biological Sciences 12 14%
Medicine and Dentistry 12 14%
Immunology and Microbiology 4 5%
Nursing and Health Professions 3 3%
Other 9 10%
Unknown 31 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 January 2018.
All research outputs
#2,638,268
of 23,305,591 outputs
Outputs from Oncogene
#822
of 10,738 outputs
Outputs of similar age
#46,491
of 339,202 outputs
Outputs of similar age from Oncogene
#23
of 101 outputs
Altmetric has tracked 23,305,591 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,738 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 339,202 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 101 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.